What is it about?
Chemoresistance of urinary bladder cancer is common, which asks for more interventions to overcome it. Through establishing a cisplatin resistant bladder cancer cell line, we identified NFkappaB signaling is constitutive activated. As a mixture of ten herbal extracts, Zyflamend can efficiently inhibit NFkappaB signaling and downregulating its downstream targets. Both cell culture and nude mice studies revealed that the treatment of Zyflamend can chemosensitize bladder cancer cells to cisplatin.
Featured Image
Why is it important?
Chemoresistance of urinary bladder cancer is a perplexing issue for clinicians. Our study revealed that constitutive activation of NFkB signaling accounts for chemoresistance of bladder cancer cells. Notably, we provided evidence that Zyflamend, as an herbal amalgam, can reverse the cisplatin resistance in vitro and in vivo. Moreover, Zyflamend treatment did not show obvious side effects to mice. Our data indicated that Zyflamend can be a promising agent to counteract bladder cancer resistance to cisplatin.
Perspectives
Since I started to work on Zyflamend to examine its anti-cancer effect on castration resistant prostate cancer in Columbia University Medical School, I was intrigued by its synergistic effect with bicalutamide. We were one of the first research groups to report that Zyflamend degrades AR and AR variant to enhance the anti-cancer effect of bicalutamide (Yan et al. Prostate 2012;72:244.). Nowadays we found that Zyflamend can also chemosensitize bladder cancer cells to cisplatin. Based on these findings and others, I am looking forward to its anti-cancer effects in clinical trial, as well as its combined treatment with other therapies, such as immunotherapy.
Dr Jun Yan
Model Animal Research Center, Nanjing University
Read the Original
This page is a summary of: Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway, OncoTargets and Therapy, July 2018, Dove Medical Press,
DOI: 10.2147/ott.s162255.
You can read the full text:
Contributors
The following have contributed to this page
